Nuvation Bio's IBTROZI® Shows Promising Long-Term Results in Lung Cancer Treatment
Nuvation Bio Inc., a company committed to advancing oncology treatments, has recently released long-term follow-up data on its leading drug, IBTROZI® (taletrectinib). This analysis, shared during the AACR Annual Meeting 2026, highlights promising results from pivotal TRUST-I and TRUST-II trials, specifically targeting patients with advanced ROS1-positive non-small cell lung cancer (NSCLC). The results reveal a median duration of response (mDOR) of 49.7 months and a median progression-free survival (mPFS) lasting 46.1 months for TKI-naïve patients, showcasing the drug's effectiveness.
One of the standout features of IBTROZI is its high confirmed objective response rate (cORR), which stands at an impressive 89.8% among TKI-naïve patients. Such results are critical for the management of ROS1-positive lung cancer, where durable responses are paramount. Dr. Lyudmila Bazhenova, an investigator in the TRUST-II study, emphasized that achieving durable responses of over four years is a primary goal for treating this condition. Additionally, the therapy demonstrated significant intracranial activity, with a response rate of 76.5% in patients with brain metastases, indicating its potential to effectively target cancer spread to the central nervous system while maintaining a manageable safety profile.
The pooled data also reflects a favorable safety profile, consistent with previous reports, where most adverse events were low-grade and resolved swiftly. In this updated follow-up, the rate of treatment discontinuations due to adverse events was just 8.5%. Notably, no new safety signals emerged with the longer follow-up duration, sending a positive message about the drug's safety in the long term.
In addition to presenting findings on tested patients, Nuvation Bio also shared preclinical data showing that taletrectinib had the ability to suppress the migration of lung cancer cells, suggesting its potential to impact not only disease progression but also its invasive capabilities.
Nuvation Bio has made significant strides since the U.S. FDA approved IBTROZI for the treatment of adults with locally advanced or metastatic ROS1+ NSCLC in June 2025, marking a pivotal moment in therapeutic options available for patients. The drug is setting a new standard of care in managing advanced lung cancer, especially in cases where traditional treatment approaches have been insufficient. It is noteworthy that IBTROZI is also available in Japan and China, further extending its impact beyond U.S. borders.
The company is actively seeking expansion opportunities for IBTROZI in the European market, where its Marketing Authorisation Application has been accepted for comprehensive review. Such initiatives underline Nuvation Bio's commitment to improving patient treatment outcomes on a global scale, reinforcing its vision of addressing some of the toughest challenges posed by cancer.
In summary, the recent presentation from Nuvation Bio illustrates the significant progress IBTROZI has made in offering hope for patients diagnosed with ROS1-positive NSCLC. With high efficacy rates, extended durations of response, and a robust safety profile, IBTROZI stands poised to redefine treatment pathways not only in lung cancer but potentially across various cancer types as ongoing research and clinical trials continue to unravel its full potential.
One of the standout features of IBTROZI is its high confirmed objective response rate (cORR), which stands at an impressive 89.8% among TKI-naïve patients. Such results are critical for the management of ROS1-positive lung cancer, where durable responses are paramount. Dr. Lyudmila Bazhenova, an investigator in the TRUST-II study, emphasized that achieving durable responses of over four years is a primary goal for treating this condition. Additionally, the therapy demonstrated significant intracranial activity, with a response rate of 76.5% in patients with brain metastases, indicating its potential to effectively target cancer spread to the central nervous system while maintaining a manageable safety profile.
The pooled data also reflects a favorable safety profile, consistent with previous reports, where most adverse events were low-grade and resolved swiftly. In this updated follow-up, the rate of treatment discontinuations due to adverse events was just 8.5%. Notably, no new safety signals emerged with the longer follow-up duration, sending a positive message about the drug's safety in the long term.
In addition to presenting findings on tested patients, Nuvation Bio also shared preclinical data showing that taletrectinib had the ability to suppress the migration of lung cancer cells, suggesting its potential to impact not only disease progression but also its invasive capabilities.
Nuvation Bio has made significant strides since the U.S. FDA approved IBTROZI for the treatment of adults with locally advanced or metastatic ROS1+ NSCLC in June 2025, marking a pivotal moment in therapeutic options available for patients. The drug is setting a new standard of care in managing advanced lung cancer, especially in cases where traditional treatment approaches have been insufficient. It is noteworthy that IBTROZI is also available in Japan and China, further extending its impact beyond U.S. borders.
The company is actively seeking expansion opportunities for IBTROZI in the European market, where its Marketing Authorisation Application has been accepted for comprehensive review. Such initiatives underline Nuvation Bio's commitment to improving patient treatment outcomes on a global scale, reinforcing its vision of addressing some of the toughest challenges posed by cancer.
In summary, the recent presentation from Nuvation Bio illustrates the significant progress IBTROZI has made in offering hope for patients diagnosed with ROS1-positive NSCLC. With high efficacy rates, extended durations of response, and a robust safety profile, IBTROZI stands poised to redefine treatment pathways not only in lung cancer but potentially across various cancer types as ongoing research and clinical trials continue to unravel its full potential.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.